论文部分内容阅读
本品是美国Sterling制药公司的Winth-rop药厂继氨吡酮(Amrinone)之后研究开发的第二个新强心药。它能抑制心脏的磷酸二酯酶,产生正性肌力使心肌收缩力加强,并能扩张外周血管,临床适用于治疗充血性心力衰竭。在动物试验中发现狗口服给药30min起效,持续6h以上,作用比氨吡酮强10～30倍;它的注射剂已于1987年12月获美国FDA批准;口服制剂尚待审批中。国内重庆医药工业研究所与中国药科大学正在研制。 [化学名称] (1)(3,4’bipyridine)-5-carbonitrile,1,6-dihydro-2-methyl-6-oxo。 (2)1,6-Dihydro-2-methyl-6oxo-(3,4’-bipyridine)-5-carbonitri
This product is the United States Sterling Pharmaceutical Company’s Winth-rop pharmaceutical factory following Amiketone (Amrinone) research and development after the second new cardiac medicine. It can inhibit the heart of phosphodiesterase, produce positive muscle strength to enhance myocardial contractility, and can expand peripheral blood vessels, clinically applicable for the treatment of congestive heart failure. In animal experiments found that the dog oral administration of 30min onset, sustained 6h above, the role of stronger than the amikacin 10 to 30 times; its injection in December 1987 by the US FDA approval; oral preparations yet to be approved. Chongqing Institute of Pharmaceutical Industry and China Pharmaceutical University are being developed. [Chemical Name] (1) (3,4’bipyridine) -5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo. (2) 1,6-Dihydro-2-methyl-6oxo- (3,4’-bipyridine) -5-carbonitri